It’s Easy To Bet On Bluebird bio Inc (NASDAQ: BLUE) For Economic Progress Over The Impending Months

In today’s recent session, 1.16 million shares of the Bluebird bio Inc (NASDAQ:BLUE) have been traded, and its beta is 0.77. Most recently the company’s share price was $1.22, and it changed around -$0.02 or -2.02% from the last close, which brings the market valuation of the company to $234.18M. BLUE at last check was trading at a discount to its 52-week high of $5.53, offering almost -353.28% off that amount. The share price’s 52-week low was $0.88, which indicates that the recent value has risen by an impressive 27.87% since then. We note from Bluebird bio Inc’s average daily trading volume that its 10-day average is 6.8 million shares, with the 3-month average coming to 9.79 million.

Bluebird bio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.77. If we narrow it down even further, the data shows that 1 out of 18 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 5 recommended BLUE as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Bluebird bio Inc is expected to report earnings per share of -$0.66 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Bluebird bio Inc (NASDAQ:BLUE) trade information

Instantly BLUE has been showing red trend so far today with a performance of -2.02% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently down -11.96% year-to-date, but still down -10.66% over the last five days. On the other hand, Bluebird bio Inc (NASDAQ:BLUE) is -22.36% down in the 30-day period. We can see from the shorts that 34.04 million shares have been sold at a short interest cover period of 2.91 day(s).

The consensus price target as assigned by Wall Street analysts is $14.13, which translates to bulls needing to increase their stock price by 91.37% from its current value. Analyst projections state that BLUE is forecast to be at a low of $5 and a high of $25.

Bluebird bio Inc (BLUE) estimates and forecasts

Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -273.70% in revenue this quarter, and will report a decrease of -323.80% in the next quarter. The year-over-year growth rate is expected to be 900.60%, up from the previous year.

Consensus estimates provided by 11 financial analysts predict the company will bring in an average of $10.8 million in revenue for the current quarter. 9 analysts expect Bluebird bio Inc to make $19.55 million in revenue for the quarter ending Mar 2024. The company’s sales for the same quarters a year ago were $62k and $2.38 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 17,319.40%. Forecasts for the next quarter put sales growth at 721.10%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 15.14%. Bluebird bio Inc earnings are expected to increase by 10.66% in 2024, but the outlook is positive 45.80% per year for the next five years.